Home › Research › Risk genes beyond APOE
MiR-124 acts as a target for Alzheimer's disease by regulating BACE1
An F, Gong G, Wang Y, Bian M, Yu L, Wei C.. Oncotarget, 2017-12-09
This paper has been retracted. The record we hold marks it as a retracted publication. Check the original source below for the retraction notice before relying on anything it reports.
Topic: Amyloid, tau and blood-test diagnosis
Although large numbers of microRNAs (miRNAs) expressed in Alzheimer disease (AD) have been detected, their functions and mechanisms of regulation remain to be fully clarified. Beta-site Amyloid precursor protein Cleaving Enzyme 1 (BACE1) has been one of the prime therapeutic targets for AD. Here, we identified that miR-124 levels are gradually decreased in AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
An, F., Gong, G., Wang, Y., Bian, M., Yu, L., & Wei, C. (2017). MiR-124 acts as a target for Alzheimer's disease by regulating BACE1. Oncotarget. https://doi.org/10.18632/oncotarget.23119
Vancouver
An F, Gong G, Wang Y, Bian M, Yu L, Wei C. MiR-124 acts as a target for Alzheimer's disease by regulating BACE1. Oncotarget. 2017. doi:10.18632/oncotarget.23119. PMID: 29371969.
BibTeX
@article{an2017-29371969,
author = {An, F. and Gong, G. and Wang, Y. and Bian, M. and Yu, L. and Wei, C.},
title = {{MiR-124 acts as a target for Alzheimer's disease by regulating BACE1}},
journal = {Oncotarget},
year = {2017},
doi = {10.18632/oncotarget.23119},
pmid = {29371969},
url = {https://doi.org/10.18632/oncotarget.23119}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Beta-site Amyloid precursor protein Cleaving Enzyme 1 (BACE1) has been one of the prime therapeutic targets for AD.
- Here, we identified that miR-124 levels are gradually decreased in AD.
- In addition, we demonstrated that miR-124 suppresses BACE1 expression by directly targeting the 3'UTR of Bace1 mRNA in vitro .
- Inhibition of miR-124 significantly increased BACE1 levels in neuronal cells.
Why it matters
This work found that miR-124 levels decrease in Alzheimer's disease and that miR-124 suppresses BACE1 expression by targeting Bace1 mRNA in vitro. This is laboratory work on a possible mechanism and does not establish a treatment for patients.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 16/100
Retracted — do not rely on it. It scored 24 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (Oncotarget) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 0 / 10 | Retracted — do not rely on it. PubMed indexes it as a Retracted Publication. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 129 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 11.7 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 3 / 6 | Cited 6.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 32 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Cheng‐Xi Wei: h-index 13 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Inner Mongolia University for Nationalities: institution h-index 108 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 29371969) |
| Free to read | 2 / 2 | Free to read |
| Total | 24 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Risk genes beyond APOE
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.